Evaluating the generalizability of a large streamlined Cardiovascular trial comparing hospitals and patients in the Dual Antiplatelet Therapy Study versus the National Cardiovascular Data Registry

Circulation: Cardiovascular Quality and Outcomes

Volumn 8, Issue 1, 2015, Pages 96-102

  Yeh, Robert W ^a,c,d   Czarny, Matthew J ^e   Normand, Sharon Lise T ^b,c,f   Kereiakes, Dean J ^g   Holmes, David R ^h   Brindis, Ralph G ⁱ   Weaver, W Douglas ^j   Rumsfeld, John S ^k   Roe, Matthew T ^l   Kim, Sunghee ^l   Driscoll Shempp, Priscilla ^d   Mauri, Laura ^b,c,d  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d HARVARD CLINICAL RESEARCH INSTITUTE   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^g The Carl & Edyth Lindner Center for Research & Education   (United States)

^h MAYO CLINIC   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j HENRY FORD HEALTH SYSTEM   (United States)

^k VETERANS AFFAIRS MEDICAL CENTER   (United States)

^l DUKE CLINICAL RESEARCH INSTITUTE   (United States)

more..

Author keywords

Clinical trial; Coronary disease; Methods; Stents

Indexed keywords

ANTITHROMBOCYTIC AGENT;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CASE MIX; CLINICAL TRIAL (TOPIC); COMORBIDITY; DIABETES MELLITUS; DRUG ELUTING STENT; FEMALE; HOSPITAL; HOSPITAL BED; HUMAN; HYPERTENSION; MALE; NATIONAL CARDIOVASCULAR DATA REGISTRY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RACE; REGISTER; RURAL AREA; SEX; SMOKING; URBAN AREA; ADVERSE EFFECTS; AGED; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEVICES; EPIDEMIOLOGY; ETHNOLOGY; HIGH VOLUME HOSPITAL; HOSPITAL BED CAPACITY; METHODOLOGY; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; UNITED STATES;

AGED; COMORBIDITY; CORONARY ARTERY DISEASE; DRUG THERAPY, COMBINATION; DRUG-ELUTING STENTS; FEMALE; HOSPITAL BED CAPACITY; HOSPITALS; HOSPITALS, HIGH-VOLUME; HOSPITALS, URBAN; HUMANS; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; REGISTRIES; RESEARCH DESIGN; SEX FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84927635770     PISSN: 19417713     EISSN: 19417705     Source Type: Journal    
DOI: 10.1161/CIRCOUTCOMES.114.001239     Document Type: Article

References (26)

1. Lauer MS. Commentary: how the debate about comparative effectiveness research should impact the future of clinical trials. Stat Med. 2012;31:3051-3053.
2. Luce BR, Kramer JM, Goodman SN, Connor JT, Tunis S, Whicher D, Schwartz JS. Rethinking randomized clinical trials for comparative effectiveness research: the need for transformational change. Ann Intern Med. 2009;151:206-209.
3. Gurwitz JH, Col NF, Avorn J. The exclusion of the elderly and women from clinical trials in acute myocardial infarction. JAMA. 1992;268:1417-1422.
4. Harris DJ, Douglas PS. Enrollment of women in cardiovascular clinical trials funded by the National Heart, Lung, and Blood Institute. N Engl J Med. 2000;343:475-480.
5. Lee PY, Alexander KP, Hammill BG, Pasquali SK, Peterson ED. Representation of elderly persons and women in published randomized trials of acute coronary syndromes. JAMA. 2001;286:708-713.
6. Rothwell PM. External validity of randomised controlled trials: "to whom do the results of this trial apply?". Lancet. 2005;365:82-93.
7. Tunis SR, Stryer DB, Clancy CM. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA. 2003;290:1624-1632.
8. Calvo G, McMurray JJ, Granger CB, Alonso-García Á, Armstrong P, Flather M, Gómez-Outes A, Pocock S, Stockbridge N, Svensson A, Van de Werf F. Large streamlined trials in cardiovascular disease. Eur Heart J. 2014;35:544-548.
9. Mauri L, Kereiakes DJ, Normand SL, Wiviott SD, Cohen DJ, Holmes DR, Bangalore S, Cutlip DE, Pencina M, Massaro JM. Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions. Am Heart J. 2010;160:1035-41, 1041.e1.
10. Masoudi FA, Ponirakis A, Yeh RW, Maddox TM, Beachy J, Casale PN, Curtis JP, De Lemos J, Fonarow G, Heidenreich P, Koutras C, Kremers M, Messenger J, Moussa I, Oetgen WJ, Roe MT, Rosenfield K, Shields TP Jr, Spertus JA, Wei J, White C, Young CH, Rumsfeld JS. Cardiovascular care facts: a report from the national cardiovascular data registry: 2011. J Am Coll Cardiol. 2013;62:1931-1947.
11. Messenger JC, Ho KK, Young CH, Slattery LE, Draoui JC, Curtis JP, Dehmer GJ, Grover FL, Mirro MJ, Reynolds MR, Rokos IC, Spertus JA, Wang TY, Winston SA, Rumsfeld JS, Masoudi FA; NCDR Science and Quality Oversight Committee Data Quality Workgroup. The National Cardiovascular Data Registry (NCDR) Data Quality Brief: the NCDR Data Quality Program in 2012. J Am Coll Cardiol. 2012;60:1484-1488.
12. Concannon TW, Nelson J, Kent DM, Griffith JL. Evidence of systematic duplication by new percutaneous coronary intervention programs. Circ Cardiovasc Qual Outcomes. 2013;6:400-408.
13. Austin PC. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Commun Stat Simul Comput. 2009;38:1228-1234.
14. Garratt KN, Lee DP, Rose EM, Windle KJ, Liao H, Nwachuku CE, Winters KJ, Bowman TS, Dawkins KD. Rationale and design of the TAXUS Liberte¯ Post-Approval Study: examination of patients receiving the TAXUS Liberté stent with concomitant prasugrel therapy in routine interventional cardiology practice. Am Heart J. 2012;163:142-8.e6.
15. Kunz LM, Yeh RW, Normand SL. Comparative effectiveness research: does one size fit all? Stat Med. 2012;31:3062-3065; discussion 3066.
16. Dhruva SS, Redberg RF. Variations between clinical trial participants and Medicare beneficiaries in evidence used for Medicare national coverage decisions. Arch Intern Med. 2008;168:136-140.
17. Heiat A, Gross CP, Krumholz HM. Representation of the elderly, women, and minorities in heart failure clinical trials. Arch Intern Med. 2002;162:1682-1688.
18. Steg PG, López-Sendón J, Lopez de Sa E, Goodman SG, Gore JM, Anderson FA Jr, Himbert D, Allegrone J, Van de Werf F; GRACE Investigators. External validity of clinical trials in acute myocardial infarction. Arch Intern Med. 2007;167:68-73.
19. Tu JV, Willison DJ, Silver FL, Fang J, Richards JA, Laupacis A, Kapral MK; Investigators in the Registry of the Canadian Stroke Network. Impracticability of informed consent in the Registry of the Canadian Stroke Network. N Engl J Med. 2004;350:1414-1421.
20. de Boer SP, Lenzen MJ, Oemrawsingh RM, Simsek C, Duckers HJ, van der Giessen WJ, Serruys PW, Boersma E. Evaluating the 'all-comers' design: a comparison of participants in two 'all-comers' PCI trials with nonparticipants. Eur Heart J. 2011;32:2161-2167.
21. Lauer MS, D'Agostino RB Sr. The randomized registry trial-the next disruptive technology in clinical research? N Engl J Med. 2013;369:1579-1581.
22. Fröbert O, Lagerqvist B, Olivecrona GK, Omerovic E, Gudnason T, Maeng M, Aasa M, Angerås O, Calais F, Danielewicz M, Erlinge D, Hellsten L, Jensen U, Johansson AC, Kåregren A, Nilsson J, Robertson L, Sandhall L, Sjögren I, Ostlund O, Harnek J, James SK; TASTE Trial. Thrombus aspiration during ST-segment elevation myocardial infarction. N Engl J Med. 2013;369:1587-1597.
23. Hess CN, Rao SV, Kong DF, Aberle LH, Anstrom KJ, Gibson CM, Gilchrist IC, Jacobs AK, Jolly SS, Mehran R, Messenger JC, Newby LK, Waksman R, Krucoff MW. Embedding a randomized clinical trial into an ongoing registry infrastructure: unique opportunities for efficiency in design of the Study of Access site For Enhancement of Percutaneous Coronary Intervention for Women (SAFE-PCI for Women). Am Heart J. 2013;166:421-428.
24. Rao SV, Hess CN, Barham B, Aberle LH, Anstrom KJ, Patel TB, Jorgensen JP, Mazzaferri EL Jr, Jolly SS, Jacobs A, Newby LK, Gibson CM, Kong DF, Mehran R, Waksman R, Gilchrist IC, McCourt BJ, Messenger JC, Peterson ED, Harrington RA, Krucoff MW. A registry-based randomized trial comparing radial and femoral approaches in women undergoing percutaneous coronary intervention: the SAFE-PCI for Women (Study of Access Site for Enhancement of PCI for Women) trial. J Am Coll Cardiol Cardiovasc Interv. 2014;7:857-867.
25. Sourgounis A, Lipiecki J, Lo TS, Hamon M. Coronary stents and chronic anticoagulation. Circulation. 2009;119:1682-1688.
26. Becker RC, Meade TW, Berger PB, Ezekowitz M, O'Connor CM, Vorchheimer DA, Guyatt GH, Mark DB, Harrington RA; American College of Chest Physicians. The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 Suppl):776S-814S.